Press Release

Increasing Incidence Of Urological Disorders Driving the Growth of the Australia HPB surgery Market

The increasing incidence of urological disorders in Australia serves as a significant driver for the urology surgery market due to the growing number of patients requiring surgical interventions. Conditions such as prostate cancer, bladder cancer, kidney stones, urinary incontinence, and Benign Prostatic Hyperplasia (BPH) have seen rising prevalence rates, particularly among the aging population. As these disorders become more common, patients are often left with limited options for management, making surgical procedures a critical component of their treatment plans. This trend stimulates demand for surgeries and necessitates the development of specialized surgical facilities and training for healthcare professionals, further expanding the market.

For instance,

  • In January 2024, according to an article published in the Cancer Australia, prostate cancer was the most commonly diagnosed cancer in Australia. Moreover, according to the same source, in 2022, it is estimated that a male has a 1 in 6 (or 17%) risk of being diagnosed with prostate cancer by the age of 85
  • In June 2022, according to an article published in the National Library of Medicine, kidney stone disease (KSD) was common and increasing in Australia, with an estimated annual incidence of 131 cases per 100,000. Such a high tendency for recurrence has prompted prioritization of preventative interventions and treatments

Moreover, the higher incidence of urological disorders emphasizes the importance of early diagnosis and intervention, which often leads to more effective and less invasive surgical options. As public and clinical awareness of urological health increases, more patients are likely to seek proactive care and timely treatment, contributing to the growth of the surgery market. With the ongoing advancements in surgical techniques and technologies, healthcare providers are better equipped to address these disorders comprehensively. Consequently, the escalating rates of urological conditions become a focal point for driving innovations in treatment options, enhancing patient outcomes, and increasing the overall demand within the urology surgery market in Australia.

Access full Report @ https://www.databridgemarketresearch.com/reports/australia-hpb-surgery-market

Data Bridge Market Research analyzes that the Australia HPB Surgery Market is expected to reach USD 277.90 million by 2032 from USD 160.55 million in 2024, growing with a substantial CAGR of 7.1% in the forecast period of 2025 to 2032.

Key Findings of the Study

Australia HPB surgery Market

Increase In The Aging Population

The increasing aging population in Australia acts as a significant driver for the urology surgery market, as older individuals are more susceptible to various urological disorders. Conditions such as Benign Prostatic Hyperplasia (BPH), prostate cancer, urinary incontinence, and kidney stones are more prevalent among the elderly. As the proportion of older adults in the population rises, the demand for urological surgeries escalates correspondingly. This demographic trend leads to a greater number of patients requiring surgical interventions and stresses the healthcare system to provide adequate resources, facilities, and specialized care tailored to the unique needs of older patients.

For instance,

  • In October 2023, according to an article published in the University of Sydney, Australia is stated to grow older, faster. Moreover, it is estimated that, by 2026, more than 22 percent of Australians will be aged over 65, which is up from 16 percent in 2020

Furthermore, an aging population often leads to an increased focus on preventive care and early diagnosis, as well as a growing acceptance of surgical options to improve quality of life. Older adults typically seek effective treatments for urological issues that significantly impact their daily activities and overall well-being. As a result, the aging population drives the demand for urological surgeries and encourages advancements in medical technology and treatment approaches within the urology surgery market in Australia.

In response to this trend, medical device manufacturers are focusing on developing innovative blood collection technologies that ensure better patient comfort, higher accuracy, and quicker results. Additionally, the trend towards preventive healthcare further amplifies the need for blood tests as individuals seek early diagnosis and monitoring, thus propelling the demand for blood collection devices in both hospitals and home-care settings.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2025 to 2032

Base Year

2024

Historic Year

2023 (Customizable 2013-2017)

Quantitative Units

Revenue in USD Million

Segments Covered

By Application (Tumor Resection and Treatment, Laparoscopic Cholecystectomy, and Others), Technology (Laparoscopic Systems & Robotic Assisted Tools, Intraoperative Ultrasound Systems For Tumor Localization, Electrosurgical and Energy-Based Devices, and Advanced Imaging Systems), Procedure Type (Laparoscopic Surgery, Robotic-Assisted Surgery, and Open Surgery), End User, (Hospitals, Specialty Cancer Hospitals, Ambulatory Surgical Centers (ASC), and Others)

Market Players Covered

Boston Scientific Corporation (U.S.), Siemens Healthineers AG (Germany), Cook (U.S.), Olympus Corporation (Japan), Stryker (U.S.), Medtronic (Ireland), GE HealthCare (U.S.), Johnson & Johnson Services, Inc. (U.S.), and Intuitive Surgical Operations, Inc. (U.S.)

Data Points Covered in the Report

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Segment Analysis

Australia HPB surgery Market is segmented into four notable segments which are based on application, procedure, technology, and end user.

  • On the basis of application, the Australia HPB surgery Market is segmented into prostate biopsy, kidney partial nephrectomy, and others

In 2025, the prostate biopsy segment is expected to dominate the market with a market share of 32.91%

Prostate cancer is one of the most commonly diagnosed cancers among men in Australia. The high incidence rates necessitate frequent prostate biopsies for early detection and diagnosis. Australia's aging population further contributes to the increasing number of prostate cancer cases, as the risk of prostate cancer rises with age. Owing to these factors, the prostate biopsy is dominating segment in 2025.

  • On the basis of technology, the market is segmented into laparoscopic systems for kidney surgeries, MRI/Ultrasound fusion technology for prostate biopsies, robotic-assisted surgical systems, ablation technologies, and others

In 2025, the laparoscopic systems for kidney surgeries segment is expected to dominate the market with a market share of 28.22%

Laparoscopic systems provide a minimally invasive option for kidney surgeries, resulting in reduced patient trauma, shorter hospital stays, and faster recovery times. These advantages have made laparoscopic procedures a preferred choice among both patients and healthcare providers. Hence, the laparoscopic systems for kidney surgeries segment is expected to dominate the market with a market share of 28.22%.

  • On the basis of procedure, the market is segmented into laparoscopic surgery, robotic-assisted surgery, and open surgery. In 2025, the laparoscopic systems for kidney surgeries segment is expected to dominate the market with a market share of 28.22%
  • On the basis of end user, the market is segmented into hospitals, urology specialty clinics, and others. In 2025, the hospital segment is expected to dominate the market with a market share of 61.87%

Major Players

Data Bridge Market Research analyzes Boston Scientific Corporation (U.S.), Siemens Healthineers AG (Germany), Olympus Corporation (Japan), Medtronic (Ireland), and Johnson & Johnson Services, Inc. (U.S.) as the major market players of the market.

Australia HPB surgery Market

Market Development

  • In November 2024, Boston Scientific Corporation announced the completion of its acquisition of Axonics, Inc., a leader in devices for urinary and bowel dysfunction. This acquisition expands Boston Scientific’s Urology portfolio, enhancing its offerings in sacral neuromodulation and tailored treatments for incontinence
  • In November 2024, Johnson & Johnson MedTech, announced that the U.S. Food & Drug Administration (FDA) has approved the VARIPULSE Platform for treating drug-resistant paroxysmal Atrial Fibrillation (AFib). This approval positions the company to expand its portfolio of innovative solutions, enhancing its market leadership and offering new therapeutic options to patients with challenging AFib cases
  • In October 2024, Boston Scientific Corporation announced FDA approval for the FARAWAVE NAV Ablation Catheter, designed for treating paroxysmal atrial fibrillation (AF), and FDA 510(k) clearance for FARAVIEW Software. These technologies integrate with the FARAPULSE PFA System and OPAL HDx Mapping System, enabling efficient cardiac mapping and therapy with a single catheter
  • In May 2024, Biosense Webster, Inc., announced the launch of CARTO 3 System Version 8, the newest iteration of its advanced three-dimensional (3D) heart mapping system used in cardiac ablation procedures. This launch strengthens the company’s position as a pioneer in cardiac technology, offering enhanced capabilities that improve procedural precision and patient outcomes, further solidifying its leadership in the cardiovascular space
  • In March 2024, Biosense Webster, Inc., announced the submission of the VARIPULSE Platform for Premarket Approval (PMA) to the U.S. Food & Drug Administration (FDA). This submission marks a significant step in advancing the platform’s approval, which will enable the company to expand its product offerings and strengthen its market presence in the growing atrial fibrillation treatment market
  • In October 2024, Medtronic announced FDA approval of the Affera Mapping and Ablation System with Sphere-9 Catheter for treating persistent atrial fibrillation (AFib) and atrial flutter. With this approval, Medtronic becomes the first to offer two PFA technologies, enhancing treatment flexibility for physicians

For more detailed information about the Australia HPB surgery Market report, click here – https://www.databridgemarketresearch.com/reports/australia-hpb-surgery-market


Client Testimonials